Nautilus Biotechnology Stock Fundamentals
| NAUT Stock | USD 1.11 0.05 4.72% |
Nautilus Biotechnology fundamentals help investors to digest information that contributes to Nautilus Biotechnology's financial success or failures. It also enables traders to predict the movement of Nautilus Stock. The fundamental analysis module provides a way to measure Nautilus Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nautilus Biotechnology stock.
Nautilus |
Nautilus Biotechnology Company Return On Equity Analysis
Nautilus Biotechnology's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Nautilus Biotechnology Return On Equity | -0.3 |
Most of Nautilus Biotechnology's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nautilus Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Nautilus Biotechnology has a Return On Equity of -0.2986. This is 98.75% lower than that of the Biotechnology sector and 99.18% lower than that of the Health Care industry. The return on equity for all United States stocks is 3.68% lower than that of the firm.
Nautilus Biotechnology Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Nautilus Biotechnology's current stock value. Our valuation model uses many indicators to compare Nautilus Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Nautilus Biotechnology competition to find correlations between indicators driving Nautilus Biotechnology's intrinsic value. More Info.Nautilus Biotechnology is rated below average in return on equity category among its peers. It is regarded fifth in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Nautilus Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Nautilus Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nautilus Biotechnology's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nautilus Biotechnology could also be used in its relative valuation, which is a method of valuing Nautilus Biotechnology by comparing valuation metrics of similar companies.Nautilus Biotechnology is currently under evaluation in return on equity category among its peers.
Nautilus Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 34.3 M | ||||
| Shares Outstanding | 126.15 M | ||||
| Shares Owned By Insiders | 33.30 % | ||||
| Shares Owned By Institutions | 49.62 % | ||||
| Number Of Shares Shorted | 283.23 K | ||||
| Price To Book | 0.64 X | ||||
| EBITDA | (79.5 M) | ||||
| Net Income | (70.78 M) | ||||
| Cash And Equivalents | 299.34 M | ||||
| Cash Per Share | 2.40 X | ||||
| Total Debt | 30.48 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 49.75 X | ||||
| Book Value Per Share | 1.66 X | ||||
| Cash Flow From Operations | (59.15 M) | ||||
| Short Ratio | 2.88 X | ||||
| Earnings Per Share | (0.56) X | ||||
| Target Price | 2.38 | ||||
| Number Of Employees | 155 | ||||
| Beta | 1.07 | ||||
| Market Capitalization | 133.72 M | ||||
| Total Asset | 242.74 M | ||||
| Retained Earnings | (273.02 M) | ||||
| Working Capital | 125.19 M | ||||
| Net Asset | 242.74 M |
About Nautilus Biotechnology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nautilus Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nautilus Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nautilus Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company was founded in 2016 and is headquartered in Seattle, Washington. Nautilus Biotechnology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nautilus Stock Analysis
When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.